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Ribonuclease L (RNase L) is a type I interferon regulated factor that can signiﬁcantly inhibit retroviruses
in vitro and may activate cytoplasmic sensing pathways to augment adaptive immunity. However, the
antiretroviral activity of RNase L remains to be validated in vivo. We investigated the role of RNaseL in
counteracting Friend retrovirus (FV) infection relative to a well-described restriction factor, Apobec3.
C57BL/6 wild-type (WT) and RNaseL knock-out (KO) mice exhibited similar acute FV infection levels
despite signiﬁcant transcriptional induction of oligoadenylate synthetase 1, which produces activators of
RNase L. Apobec3 KO mice showed higher FV infection levels relative to WT mice, but deletion of RNaseL
in Apobec3 KO mice did not augment FV infection. Moreover, RNaseL did not inﬂuence FV-speciﬁc IgG
responses and recovery from viremia by 28 days post-infection. The results suggest that RNase L is not an
evolutionarily-conserved host defense mechanism to counteract retroviruses in vivo.
& 2013 Elsevier Inc. All rights reserved.Introduction
The long-standing evolutionary conﬂict between retroviruses
and mammalian hosts led to the emergence of host factors that
have intrinsic antiretroviral activity (Duggal and Emerman, 2012).
These ‘restriction factors’ could directly inhibit speciﬁc steps of the
retrovirus life cycle and appear to act as effectors of the type I
interferon (IFN) response. Several restriction factors that include
APOBEC3G, Tetherin/BST-2, TRIM5α and SAMHD1 that can inhibit
HIV-1 replication were identiﬁed in the past decade and have
since been the subject of intense study (Malim and Bieniasz, 2012).
However, prior to the identiﬁcation of these antiviral factors, the
type I IFN antiviral response was associated with double-stranded
RNA (dsRNA)-dependent ribonuclease activity (Lengyel et al.,
1980). This ribonuclease activity was later attributed to the
sequential action of two enzymes, oligoadenylate synthetase
(OAS) and its main downstream effector, ribonuclease L (RNase L)
(Chakrabarti et al., 2011).
RNase L is an 84 kDa latent enzyme composed of ankyrin
repeats, a kinase homology domain and a ribonuclease domainll rights reserved.
seases, University of Colorado
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L. Santiago).(Zhou et al., 1993). Following dsRNA activation, OAS synthesizes
2′-5′ oligoadenylates (2-5A) which bind to RNase L, leading to
RNase L dimerization (Dong and Silverman, 1995). RNase L dimers
cleave both viral and host RNAs preferably at UU or UA dinucleo-
tides (Floyd-Smith et al., 1981; Wreschner et al., 1981) in single-
stranded RNA loops of hairpin structures (Han et al., 2004).
Cleavage of viral RNA is expected to directly inhibit virus replica-
tion, whereas cleavage of host RNAs (Silverman et al., 1983) was
linked to the ability of RNase L to mediate apoptosis (Castelli et al.,
1998). In addition, the cleavage of viral and host RNAs by RNase L
may liberate RNA species that could activate cytoplasmic RNA
sensing pathways. In particular, the generation of small self-RNAs
(Malathi et al., 2007), as well as the Hepatitis C virus svRNA
fragment (Malathi et al., 2010), results in the activation of the RNA
sensor RIG-I to trigger IFN-β production. Thus, RNase L may further
augment innate immunity, which in turn could prime a more
effective adaptive immune response.
Since retroviruses harbor two RNA genomes per virion that
form extensive secondary structures (for example, see Watts et al.,
2009), RNase L was considered as a potential antiretroviral factor.
Several in vitro studies supported this hypothesis. Upregulation of
2-5A in HIV infected T cell lines correlated with the detection of
HIV RNA cleavage products (Schroder et al., 1989). Treatment of
HIV-infected target cells ex vivo with nuclease-resistant 2-5AN6B
resulted in inhibition of HIV-1 replication (Dimitrova et al., 2007).
Fig. 1. Mouse RNase L potently inhibits F-MuLV in vitro. Expression plasmids
encoding murine Apobec3, RNaseL or empty vector were co-transfected with an
F-MuLV molecular clone, pLRB302, into 293T cells. Serial 3-fold dilutions of the
supernatants were used to infect Mus dunni cells, and after 48 h, cells were ﬁxed and
stained with a monoclonal antibody (MAb 720) against the F-MuLV envelope protein.
Foci were counted and infectious titers were calculated per ml of supernatant. Mean
fold-differences relative to vector control are shown. P values were calculated using
2-tailed Student’s t test, with po0.05 considered statistically signiﬁcant.
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RNase L expression plasmids with HIV-1 provirus, diminished HIV-1
replication (Maitra and Silverman, 1998).
For several RNA viruses such as West Nile virus and encepha-
lomyocarditis virus, the antiviral role of RNase L was strengthened
following experimental infections revealing higher virus replica-
tion in RNaseL knock-out (KO) versus wild-type (WT) mice (Zhou
et al., 1997; Samuel et al., 2006). Thus, investigating the role of
RNase L in mouse retrovirus infection models may provide insights
on the antiretroviral properties of RNase L from a more physiolo-
gical context. Friend retrovirus (FV) infection of mice represents
one of the most well-described in vivo models of retroviral
pathogenesis, paving the way for the initial identiﬁcation of host
antiretroviral genes and understanding salient features of retro-
virus adaptive immune responses (Nair et al., 2011; Halemano
et al., 2013). FV is an ecotropic gammaretrovirus complex that
consists of Friend murine leukemia virus (F-MuLV) and spleen
focus forming virus (SFFV) that establishes chronic infection in
mice. F-MuLV encodes a fully functional provirus, whereas the
pathogenic component, SFFV, is replication-defective and is pre-
sent in the complex at 4100-fold lower levels than F-MuLV
(Steeves et al., 1971; He et al., 2008). Given that F-MuLV is essential
for replication of the FV complex, detection assays for FV infection
are directed primarily against F-MuLV proteins or nucleic acids
(Robertson et al., 1991; Dittmer et al., 2002; Santiago et al., 2011;
Smith et al., 2011). Thus, the FV infection levels determined from
most in vivo infections, as well as this study, refer speciﬁcally to
the F-MuLV component.
Recently, the FV infection model was used to validate the
physiological importance and evolutionary conservation of intrin-
sic restriction factors and innate sensing pathways. FV infects
multiple cells in immune compartments, including erythroblasts,
myeloid cells, B cells and to a lesser extent, T cells (Dittmer et al.,
2002; Santiago et al., 2010). Thus, intrinsic resistance factors
expressed in these susceptible cells could potentially inhibit FV
infection. Using knock-out mice, our group and others demon-
strated a signiﬁcant role for an enzyme known as Apobec3 in
inhibiting acute FV replication (Santiago et al., 2008, 2011; Takeda
et al., 2008; Tsuji-Kawahara et al., 2010; Smith et al., 2011).
Apobec3 is a deoxycytidine deaminase that could get packaged
into retrovirus particles and inhibits retrovirus replication in the
next target cell (Malim and Bieniasz, 2012). Apobec3 likely inhibits
FV virion infectivity by blocking early reverse transcription rather
than inducing lethal G-to-A hypermutation (Smith et al., 2011).
Interestingly, Apobec3 maps within the region in chromosome 15
encoding a classical resistance gene, Recovery from Friend virus
gene 3 or Rfv3, which dictates recovery from FV infection by
promoting a stronger neutralizing antibody response (Chesebro
and Wehrly, 1979; Hasenkrug et al., 1995). Subsequently, our group
and others reported that mice deﬁcient in the B6 Apobec3 gene
developed weaker FV-speciﬁc antibody responses (Santiago et al.,
2008; Tsuji-Kawahara et al., 2010; Smith et al., 2011), supporting
the notion that Rfv3 is encoded by Apobec3. Thus, the FV infection
model was also instrumental in demonstrating that an innate
restriction factor could modulate an adaptive immune response.
The expression of restriction factors in virus-susceptible target
cells provides a rationale for testing a potential inhibitory role.
Similar to Apobec3 (Takeda et al., 2008; Santiago et al., 2010; Tsuji-
Kawahara et al., 2010), RNase L is expressed highly in immune
compartments that include the spleen (Zhou et al., 1997), a
primary site of FV replication in vivo (Dittmer et al., 2002;
Santiago et al., 2010). In microarray studies, RNase L mRNA was
detected in multiple immune cell subpopulations in the bone
marrow (BM) including erythroblasts, myeloid cells, B cells and T
cells (Konuma et al., 2011; Gene Expression Omnibus Proﬁle
75447109 and 75447110). Similarly, Apobec3 expression wasdocumented in these immune cell types (Santiago et al., 2010;
Tsuji-Kawahara et al., 2010). Thus, the FV infection model repre-
sents a suitable experimental platform to compare the role of
RNase L versus Apobec3 in counteracting retrovirus infection and
inﬂuencing adaptive immunity in vivo.Results
RNase L potently restricts F-MuLV in vitro
We initially tested if murine RNase L has in vitro activity against
F-MuLV, the component of FV complex that is essential for
replication. Expression plasmids containing RNaseL and/or Apo-
bec3 from B6 mice were co-transfected with an F-MuLV molecular
clone, pLRB302 (Portis et al., 1992), at an equimolar ratio in 293T
cells. After 48 h, supernatants were harvested and titered in Mus
dunni cells using a focal infectivity assay. The focal infectivity assay
would detect not only a decrease in virion infectivity due to
Apobec3, but also a decrease in viral production, as would be
expected with RNase L activity in the producer cell. As shown in
Fig. 1, co-transfection with RNaseL expression plasmid led to a
signiﬁcant 2.8-fold decrease in viral titer relative to the vector
control, whereas Apobec3 inhibited by only 1.3-fold. Thus, RNase L
signiﬁcantly inhibited F-MuLV to a greater degree than Apobec3.
Interestingly, co-transfection of F-MuLV with both Apobec3 and
RNaseL expression constructs led to a 6.6-fold inhibition, higher
than the product of the individual fold-inhibition values (3.6-fold).
This ﬁnding raised the possibility of synergism between Apobec3
and RNase L antiretroviral activity in vitro.
RNase L is not a potent antiretroviral factor compared to Apobec3
in vivo
To determine whether the in vitro ﬁndings in Fig. 1 apply
in vivo, B6 WT and RNaseL KO mice were infected with FV complex
and analyzed 7 days later. Since B6 Apobec3 KO mice were more
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Takeda et al., 2008; Tsuji-Kawahara et al., 2010; Smith et al., 2011),
B6 Apobec3 KO mice were also infected in parallel as an internal
positive control. Recently, we reported that B6 Apobec3 might
mask the activity of a potent Tetherin variant (Barrett et al., 2012).
To exclude the possibility that B6 Apobec3 may mask the anti-
retroviral activity of RNaseL, and to test whether Apobec3 and
RNase L could synergistically inhibit FV as suggested in Fig. 1, mice
doubly deﬁcient in Apobec3 and RNaseL (double KO) were also
generated and infected with FV.
WT, RNaseL KO, Apobec3 KO and double KO mice were inocu-
lated with FV and samples were analyzed at 7 dpi (Fig. 2A). Several
virological assays were utilized in an effort to capture an effect of
RNase L in different steps of the retroviral life cycle as outlined in
the Materials and Methods section. FV infection levels based onFig. 2. RNaseL does not signiﬁcantly impact acute FV infection even in the absence o
double KO mice were sacriﬁced at 7 dpi for analyses. Data were pooled from three indep
34 and the percent of FV infected cells was determined by ﬂow cytometry. (C) BM cellul
RNA copies, normalized to beta-actin mRNA copies. Log10 values are shown. (D) FV G
viremia. Plasma (5 ml) were inoculated intoMus dunni cells, and after 48 h, DNA was extr
to 100 ng of DNA input. Log10 values are shown. Dashed lines correspond to the detectio
correspond to mean values. Differences between pairs of experimental groups were evaluﬂow cytometry, cellular viral RNA and infectious viremia were
signiﬁcantly different between the four groups of mice based on
ANOVA (Fig. 2B–E). In contrast, spleen mass and BM proviral loads
were not signiﬁcantly different (Supplementary Fig. 1). As
expected, B6 Apobec3 KO mice had signiﬁcantly higher FV infec-
tion levels in the BM (Fig. 2B–C) and spleen (Fig. 2D) compared to
WT mice. B6 Apobec3 KO mice also had higher infectious viremia
in the plasma (Fig. 2E). In contrast, RNaseL KO mice had similar BM
FV Glyco-Gag+ cells (Fig. 3B), BM cellular viral RNA load (Fig. 2C),
spleen FV Glyco-Gag+ cells (Fig. 2D) and plasma infectious viremia
(Fig. 2E) compared to WT mice. Removal of RNaseL in Apobec3 KO
mice likewise did not result in higher FV replication relative to B6
Apobec3 KO mice (Fig. 2B–E). Intriguingly, BM cellular viral RNA
levels were signiﬁcantly lower in double-KO versus B6 Apobec3 KO
mice (Fig. 2C). However, this was not observed with otherf Apobec3. (A) Infection timeline. WT, RNaseL KO, Apobec3 KO, and RNaseL/Apobec3
endent infection cohorts. (B) BM FV+ cells. Glyco-Gag+ cells were stained with MAb
ar viral RNA load. RNA was extracted from BM and qPCR was used to determine FV
lyco-Gag+ splenocytes, stained for ﬂow cytometry as in (B). (E) Infectious plasma
acted and qPCR was used to determine the amount of FV DNA. Data was normalized
n limit of the assay. For all panels, each dot corresponds to an infected mouse, bars
ated using 2-tailed Student’s t test, with po0.05 considered statistically signiﬁcant.
Fig. 3. RNaseL does not signiﬁcantly inhibit acute FV infection in target cell subpopulations. WT, RNaseL KO, Apobec3 KO, and double KO mice were infected with 104
SFFU of FV, and at 7 dpi, BM and splenocytes were subjected to ﬂow cytometric analyses. Data were pooled from three independent infection cohorts. BM (panels A to C) and
spleen (panels D to F) were stained with antibodies against myeloid cells (CD11b; panels A and D), B cells (CD19; panels B and E), and erythroid cells (Ter119; panels C and F).
FV expression was detected using MAb 34. For all panels, each dot corresponds to an infected mouse, and bars correspond to mean values. Differences between pairs of
experimental groups were evaluated using 2-tailed Student’s t test, with po0.05 considered statistically signiﬁcant.
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reveal that in contrast to Apobec3, RNaseL does not signiﬁcantly
inhibit acute FV infection in vivo.
RNase L does not signiﬁcantly inhibit FV in speciﬁc immune cell
subpopulations
RNase L did not have a signiﬁcant effect on FV infection of total
BM and spleen cells. However, an effect of RNase L on speciﬁc cell
subpopulations cannot be excluded. We therefore determined the
levels of FV infection in myeloid (CD11b+), B cell (CD19+),
erythroblast (Ter119+) and T cell (CD3+) subsets by ﬂow cytome-
try. In contrast to myeloid and B cell subpopulations (Fig. 3), no
signiﬁcant differences between each genotype in FV infectionlevels were observed for T cells by ANOVA (Supplementary
Fig. 2). As expected, B6 Apobec3 KO mice had signiﬁcantly higher
FV infection levels in myeloid and B cells in both the BM and
spleen (Fig. 3A–B, D–E). Of note, B6 Apobec3 had no signiﬁcant
impact on FV replication in BM erythroblasts (Fig. 3C), and only
approached statistical signiﬁcance for splenic erythroblasts
(p¼0.052; Fig. 3F). Thus, the antiretroviral impact of B6 Apobec3
in bulk BM and spleen was likely due to an effect on myeloid and B
cell subpopulations. The data on B cells is consistent with another
study (Tsuji-Kawahara et al., 2010). The erythroblast data con-
trasted from results obtained with FV/LDV infections of
(B6BALB/c)F1 and (B6A.BY)F1 mice. In these splenomegaly-
susceptible strains, B6 Apobec3 had a signiﬁcant effect on FV
Glyco-Gag+ erythroblasts (Santiago et al., 2010; Smith et al.,
S.X. Li et al. / Virology 443 (2013) 134–1421382011). Importantly, RNaseL deﬁciency did not signiﬁcantly inﬂu-
ence FV replication in myeloid (Fig. 3A and D), B cell (Fig. 3B and
E), erythroblast (Fig. 3C and F) and T cell (Supplementary Fig. 2)
subsets, either in the pure B6 or B6 Apobec3 KO backgrounds in
both the BM and the spleen. Thus, RNase L does not signiﬁcantly
inhibit acute FV infection in speciﬁc cell subsets.
RNase L does not signiﬁcantly inhibit FV in the context of LDV co-
infection
The FV stock utilized in Figs. 2 and 3 lacked LDV, an endemic
mouse RNA virus found in the classical FV stocks (Robertson et al.,
2008). LDV is a potent inducer of type I IFNs (Ammann et al., 2009;
Gerlach et al., 2006; Duley et al., 2012), and could modulate the
immune response against FV as revealed in comparative studies of
FV versus FV/LDV infections (Robertson et al., 2008; Marques et al.,
2008; Duley et al., 2012). Since RNase L and its activator, OAS1,
could be induced by type I IFNs (Zhou et al., 1993; Harper et al.,
2013), FV/LDV infection of WT versus RNaseL KO mice may yield a
different acute FV infection outcome. We therefore infected B6 WT
and RNaseL KO mice with FV/LDV and evaluated FV infection levels
at 7 dpi. The results revealed that B6 WT and RNaseL KO mice had
similar FV infection levels (Supplementary Fig. 3). In addition, no
signiﬁcant differences in FV infection were found in erythroblasts,
myeloid cells, B cells and T cells, although a trend for higher FV
infection in RNaseL KO mice was observed in myeloid cells
(p¼0.08; Supplementary Fig. 4). Thus, in the context of augmen-
ted type I IFN induction due to LDV co-infection, RNase L still did
not have a signiﬁcant impact on acute FV replication in vivo.
FV infection induces OAS1a transcription independent of RNase L and
LDV co-infection
RNase L is highly expressed in multiple immune compartments
(Zhou et al., 1993), but RNase L activity requires dimerizationFig. 4. Transcriptional induction of OAS1a following FV infection in WT and RNase
qPCR, normalizing for actin levels. Fold-induction levels were normalized against the
(C) Spleen OAS1a mRNA levels. Statistical tests were performed using a 2-tailed Student
deviations from mean OAS1a levels from three mice each. For each mouse, mean OAS1athrough cross-linking by 2-5A, which is synthesized by OAS1.
Insufﬁcient RNase L activation, rather than expression, may there-
fore account for the lack of inhibitory activity of RNase L against FV
in vivo. However, 2-5A is highly unstable in cells due to endogen-
ous phosphodiesterase and phosphatase activities (Player and
Torrence, 1998; Kubota et al., 2004). Thus, as an indirect indicator
for RNase L activation, we measured the induction of OAS1
following FV infection.
Murine OAS1 is comprised of several related genes, of which
only OAS1a and OAS1g were reported to synthesize 2-5A (Kakuta
et al., 2002). B6 WT and RNaseL KO mice were infected with either
FV/LDV or FV (n¼3 mice each), and after 24 h, OAS1a levels were
compared to mock-infected controls (Fig. 4A). In the BM, FV
infection induced OAS1a expression 20-fold independent of
LDV-coinfection and the presence/absence of RNaseL (Fig. 4B). In
the spleen, FV induced OAS1a transcription to a lesser extent
(12-fold), but the OAS1a induction levels relative to mock were
statistically signiﬁcant. No difference was observed between the
OAS1a induction levels in WT versus RNaseL KO mice. These data
suggest that the lack of antiretroviral effect by RNaseL was not due
to the lack of OAS1a expression.
RNase L does not inﬂuence FV-speciﬁc IgG responses
The results above revealed that RNase L is not a potent innate
antiretroviral restriction factor. However, even low-level RNase L
activity could liberate RNA fragments that could activate innate
cytoplasmic sensing pathways (Malathi et al., 2007, 2010) and
enhance adaptive immunity. Thus, we investigated if RNase L
could promote adaptive immunity. We focused on FV-speciﬁc IgG
antibodies against native virions since this is a phenotype that was
inﬂuenced by B6 Apobec3 (Santiago et al., 2008; Tsuji-Kawahara
et al., 2010; Smith et al., 2011). Thus, B6 Apobec3 KO mice could
again serve as an internal positive control. At 7 dpi, we observed
signiﬁcantly lower FV-speciﬁc IgG endpoint titers in B6 Apobec3L-deﬁcient mice. (A) Timeline. Relative OAS1a transcript levels were measured by
mean OAS1a expression levels in uninfected mice. (B) BM OAS1a mRNA levels.
’s t test, with *, po0.05, **, po0.01, and ***, po0.001. Bars correspond to standard
levels were obtained from three technical replicates.
Fig. 5. RNaseL did not signiﬁcantly inﬂuence the FV-speciﬁc IgG response or recovery from FV viremia. Mice were infected with 104 SFFU of FV and plasma FV-speciﬁc
IgG titers at indicated timepoints were analyzed by endpoint ELISA against native FV virions. (A) 7 dpi IgG titers from groups of mice described in Figs. 3 and 4. (B) Endpoint
IgG titers at 14 and 28 dpi. The data pooled from two independent experiments. (C) Plasma viral RNA load at 28 dpi from the same mice in (B) were analyzed by qPCR. For all
panels, each dot corresponds to an infected mouse, and bars correspond to mean values. Differences between pairs of experimental groups were evaluated using 2-tailed
Student’s t test, with po0.05 considered statistically signiﬁcant.
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Apobec3 KO genetic backgrounds, RNaseL deﬁciency had no effect
on early FV-speciﬁc IgG titers (Fig. 5A).
We next compared the FV-speciﬁc IgG response at 14 and
28 dpi in two new cohorts of B6 WT and RNaseL KO mice. As
shown in Fig. 5B, there was a signiﬁcant increase in FV-speciﬁc IgG
titer from 14 to 28 dpi, consistent with the development of FV-
speciﬁc antibody responses. However, in both timepoints, there
was no signiﬁcant difference in FV-speciﬁc IgG titers between WT
and RNaseL KO mice (Fig. 5B).
RNase L does not promote recovery from FV viremia
It is possible that a signiﬁcant impact of RNaseL on adaptive
immunity, particularly T cell responses, was missed. However, if
these adaptive immune responses were signiﬁcantly augmented
by RNase L, a concomitant increase in viremia at later timepoints
post-infection should be expected in RNaseL KO mice. We there-
fore evaluated the plasma viral RNA load at 28 dpi, and found no
signiﬁcant difference between WT and RNaseL KO mice (Fig. 5C).Similar results were obtained at 14 dpi (data not shown). Thus,
RNase L did not promote recovery from FV viremia.Discussion
RNase L was among the ﬁrst effectors of the type I IFN antiviral
response that was molecularly cloned (Zhou et al., 1993) but its
role in restricting retroviruses remains surprisingly unclear. The
recent identiﬁcation of potent retrovirus restriction factors that
are antagonized by retrovirus-encoded proteins (Malim and
Bieniasz, 2012) may have shifted focus away from RNase L, which
currently does not have a bona ﬁde retroviral antagonist. However,
in theory, the highly folded retroviral RNA genome should be
susceptible to RNase L, and results from in vitro studies (Schroder
et al., 1989; Maitra and Silverman, 1998; Dimitrova et al., 2007)
supported this notion. However, none of these studies directly
tested RNaseL antiretroviral activity in vivo.
In this study, we utilized the FV infection model and RNaseL KO
mice to investigate the in vivo antiretroviral potency of RNase L. As
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contrast, RNase L did not signiﬁcantly inhibit acute FV replication
in vivo, using a variety of assays that were speciﬁc to the F-MuLV
component of the FV complex. The disconnect between the in vitro
versus in vivo antiretroviral potency of RNase L against F-MuLV
mirrored our recent ﬁndings with Tetherin. In backcrossed mice, a
Tetherin variant that potently restricted F-MuLV in vitro signiﬁ-
cantly inhibited FV complex in vivo only in the context of weak
Apobec3 activity (Barrett et al., 2012). Moreover, IFN-α treatment
inhibited acute FV replication primarily through Apobec3, despite
the fact that Tetherin and OAS1 were highly induced (Harper et al.,
2013). These ﬁndings led us to propose a ‘restriction factor
hierarchy’, whereby potent restriction factors such as B6 Apobec3
may mask the activity of other innate restriction factors (Barrett
et al., 2012). The notion of a restriction factor hierarchy provided a
rationale for testing the impact of RNase L in a B6 Apobec3 KO
background: by removing B6 Apobec3, the antiretroviral activity of
RNaseL may be unleashed. However, even in B6 Apobec3 KO mice,
RNaseL did not signiﬁcantly inhibit FV replication. Co-infection
with LDV, a potent type I IFN inducer, likewise did not result in a
signiﬁcant effect of RNase L against acute FV infection in vivo.
Altogether, these data suggest that RNase L is not a signiﬁcant
antiretroviral factor in the FV infection model. Alternatively, RNase
L may occupy a lower position in the restriction factor hierarchy
than Apobec3 or Tetherin. The results highlight the need for
caution in extrapolating data on the in vitro antiviral activity of
restriction factors to more physiologically relevant biological
systems.
The data revealed that RNaseL did not have a signiﬁcant impact
on acute FV infection. However, minor restriction effects could
have a cumulative impact if sustained during the course of
infection. RNase L may also liberate self and FV RNA fragments
that could potentiate adaptive immunity (Malathi et al., 2007,
2010). However, at later timepoints, FV infection and FV-speciﬁc
IgG responses were similar between WT and RNaseL KO mice.
Thus, RNase L did not signiﬁcantly inﬂuence FV recovery and
humoral immunity in vivo, raising doubts on the biological
signiﬁcance of subtle inhibitory effects that may have been missed
by the battery of virological tests utilized in this study.
It should be noted that the lack of RNase L activity against FV
infection of mice might not necessarily extend to other murine
retrovirus infections such as mouse mammary tumor virus
(MMTV), Moloney MLV, CasFrKP MLV and LP-BM5 (Murine AIDS).
In addition to FV infection, Apobec3 exhibited a signiﬁcant impact
on acute infection levels of MMTV, Moloney MLV, CasFrKP MLV
and LP-BM5 (Okeoma et al., 2008; Low et al., 2009; Kolokithas
et al., 2010; Jones et al., 2012). Together, these studies strengthen
the importance of Apobec3 as a potent antiretroviral restriction
factor in mice. Thus, it would be of interest to test the impact of
RNase L against other murine retroviruses. However, even if RNase
L had an impact against these other retroviral infections, the lack
of RNase L activity against FV would imply that RNase L would
have a more retrovirus-speciﬁc effect.
Along the same lines, we note the limitations of extrapolating
the FV infection results to pathogenic human retrovirus infections
such as HIV-1 and HTLV-I. Sequence differences that affect RNA
folding between these retroviruses may confer different sensitiv-
ities for RNase L cleavage. Amino acid differences between human
and mouse RNase L may likewise limit extrapolation of these
results between species. However, human and mouse RNase L
could signiﬁcantly inhibit HIV-1 and F-MuLV in vitro, respectively,
and the RNaseL KO mice used in this study exhibited higher
susceptibility to RNA viruses (Zhou et al., 1997; Samuel et al.,
2006). These ﬁndings argue against the notion that mouse RNase L
may have an inherent defect that would invalidate its relevance to
human RNase L function. Retroviruses have been co-evolving withmammalian hosts for millennia, and many innate antiviral
mechanisms, including Apobec3 as conﬁrmed in this study, are
conserved between mice and humans. Thus, the data suggests that
RNase L is not an evolutionarily conserved host defense mechan-
ism against retroviruses in vivo.
Insights on the evolutionary conservation of antiviral mechan-
isms may have practical implications for the rapidly expanding
ﬁeld of innate retrovirus restriction factor biology. The list of type I
IFN effectors have signiﬁcantly grown through large-scale in vitro
screens (Schoggins et al., 2011; Liu et al., 2012), and making sense
of these diverse restriction mechanisms – all of which appear to
have potent antiretroviral activities in vitro – has become an
important challenge. In this regard, the FV infection model may
provide critical insights on how putative antiretroviral factors
operate in an in vivo context. The identiﬁcation of potent and
evolutionarily conserved antiretroviral mechanisms may inform
which innate factors to exploit for novel therapies and basic
vaccine discovery against pathogenic human retroviruses.Materials and methods
Mice
C57BL/6 (B6) WT mice were purchased from The Jackson
Laboratory. RNaseL KO mice were generated by targeted gene
disruption (Zhou et al., 1997) and backcrossed for 10 generations
into B6. Apobec3 KO mice were generated from the XN450 gene-
trap embryonic stem cell line (BayGenomics) (Santiago et al.,
2008) and backcrossed for nine generations into B6. B6 Apobec3
and B6 RNaseL KO mice were intercrossed to generate double KO
mice. This study was approved by the Institutional Animal Care
and Use Committee at the University of Colorado [Permit Number
B-89709(10)1E].
Cell culture
Mus dunni and 293T cells were maintained in DMEM (Media-
tech) with 2% penicillin/streptomycin/glutamine (Mediatech) and
10% fetal bovine serum (FBS; Gemini).
Co-transfection of FV, RNase L and Apobec3
An amount of 500 ng of the F-MuLV molecular clone pLRB302
was co-transfected with 500 ng of p3FLAG-CMV-14 (Sigma)
vector or expression constructs encoding B6 Apobec3 (Santiago
et al., 2008) or B6 RNaseL (pFS164, from Thomas Michiels,
Universite Catholique de Louvain) into 293T cells using Fugene 6
(Promega). The ﬁnal concentration of DNA was held constant at
1.5 mg, using the vector control as ‘ﬁller’ DNA. After 2 days, super-
natants were collected from the transfected 293T cells. To quantify
FV infectious titers, serial dilutions of the supernatants were used
to infectMus dunni cells plated in 48-well plates in the presence of
4 mg/ml polybrene (Sigma). At 2 days post-infection (dpi), the cells
were ﬁxed with 95% ethanol and stained with F-MuLV envelope-
speciﬁc MAb 720 (Robertson et al., 1991). Foci were developed
using a horseradish-peroxidase conjugated anti-mouse IgG and 3-
amino-9-ethylcarbazole (Sigma) substrate. Foci were counted to
determine the infectious titer and normalized to input ml of
supernatant.
Virus stocks and FV infection
Two types of B-tropic FV were used in this study: (1) an FV
stock containing only F-MuLV and SFFV (also referred to as ‘LDV-
free FV’ in prior publications); and (2) the classical ‘FV/LDV’ stock
S.X. Li et al. / Virology 443 (2013) 134–142 141containing F-MuLV, SFFV, and a co-infecting endemic RNA virus,
lactate dehydrogenase-elevating virus (LDV) (Robertson et al.,
2008; Halemano et al., 2013). FV stocks were prepared and titered
in BALB/c mice as described (Santiago et al., 2008). Mice (2 to
4 months old) were infected intravenously via the retro-orbital
route with 104 spleen focus forming units (SFFU) of FV complex
and mice were sacriﬁced at indicated timepoints for analysis.Viral load quantiﬁcations
The quantitative PCR (qPCR) methods for measuring proviral
DNA copy numbers and plasma infectious viremia were speciﬁc for
the F-MuLV helper virus and described previously (Smith et al.,
2011; Harper et al., 2013). Proviral DNA levels provide an estimate
of the number of integrated proviruses per cell (Smith et al., 2011).
Plasma infectious viremia corresponds to the levels of reverse
transcripts produced in target Mus dunni cells following inocula-
tion with 5 ml of plasma (Harper et al., 2013). Cellular viral RNA
levels indicate the abundance of retroviral RNA transcripts in
productively infected cells, which may be susceptible to RNase L
cleavage. Cellular viral RNA load was measured from RNA
extracted from BM cells using the RNeasy Kit (Qiagen) and eluted
in RNase-free water. qPCR was performed as described for the
plasma viral load assay (Santiago et al., 2011; Smith et al., 2011).
Data were normalized to beta-actin RNA, detected using Mouse.B-
actin.sense: 5′-GGCACCACACCTTCTACAATG; Mouse.B-actin.anti-
sense: 5′-GGGGTGTTGAAGGTCTCAAAC; and Mouse.B-actin.probe:
FAM-TGTGGCCCCTGAGGAGCACCC-TAMRA.Flow cytometry
BM and spleen cells were stained with FV Glyco-Gag speciﬁc
MAb 34 (Chesebro et al., 1983) for ﬂow cytometry as described
(Smith et al., 2011) and adapted from a previous study (Dittmer
et al., 2002). The levels of FV Glyco-Gag+ cells measured by ﬂow
cytometry provides a measure of cellular infection and spread
based on viral protein production. PBS (Mediatech) with 1% FBS
was used to wash the cells. Cells were co-stained with Ter119-FITC
(clone TER-119, BD Biosciences), CD3-Alexa700 (17A2, BD Bios-
ciences), CD19-PerCP-Cy5.5 (6D5) (Biolegend), CD11b–PE (CF594,
BD Biosciences), and anti-mouse IgG2b-APC (Columbia Bios-
ciences). The stained cells were analyzed in an LSR-II ﬂow
cytometer (BD Biosciences), collecting 200,000–250,000 events
per sample. Data was analyzed using the Flowjo software (Trees-
tar), gating on live cells followed by singlet discrimination. Cells
from uninfected mice were used to gate FV+ cells.OAS1a induction
RNA from 1 dpi BM and spleen samples using the RNAEasy kit
(Qiagen) and cDNA was synthesized using the Quantiscript kit
(Qiagen). cDNA (20 ng/25 ml reaction) was added to 1 Quantitect
SYBR qPCR Mastermix (Qiagen) with a ﬁnal concentration of
5 pmol each of the following primers: Oas1a.Forward- 5′-CTGCAT-
CAGGAGGTGGAGTT-3′ and Oas1a.Reverse- 5′-GGATGGCATA-
GATTCTGGGA-3′ or Actin.Forward 5′-CTCCATCGTGGGCCGC-3′ and
Actin.Reverse 5′-CCAGTTGGTAACAATGCCATGTTC-3′. qPCR was
performed in a Bio-rad CFX96 cycler using the following condi-
tions: 95 1C for 15 min, 40 cycles of 95 1C for 15 s and 60 1C for
1 min. Melt curve analysis was performed to verify speciﬁc
ampliﬁcation. Fold-inductions were calculated using the ΔΔCt
method.ELISA
Enzyme-linked immunosorbent assays were performed as
described (Smith et al., 2011). Endpoint IgG titers were calculated
as the plasma dilution corresponding to 2 the PBS background
from each plate using best-ﬁt nonlinear regression (GraphPad
Prism 5.0).
Statistical analysis
Data were ﬁrst tested for normality using the Kolmogorov–
Smirnov test. Data with a normal distribution were evaluated
using a 2-tailed unpaired Student’s t test. Otherwise, the nonpara-
metric 2-tailed Mann–Whitney U test was used. Differences with
po0.05 were considered statistically signiﬁcant. Multi-cohort
datasets were ﬁrst subjected to one-way analysis of variance
(ANOVA). Only datasets with po0.05 by ANOVA were analyzed
for differences between pairs of groups using a 2-tailed Student’s t
test. All calculations were performed using Prism 5.0 (GraphPad).Acknowledgments
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